Biotech sector keeps surging / Cancer drug news and FDA approvals create optimism Industry observers say the sector’s sea change from pessimism to optimism comes from two sources: Good news about experimental cancer drugs from a major scientific meeting this month; and a set of recent approvals by the Food and Drug Administration, whose new […]
Early stage biotechnology collaborations The range of deals an early stage biotechnology company may enter into is wide (see box ‘What is an early stage biotechnology collaboration?’). This chapter examines, by reference to a few of the types of agreements that an early stage company may enter into, some of the key intellectual property (IP) […]
FDA chief looks to speed diabetes, obesity drugs Mark McClellan, commissioner of the Food and Drug Administration, said he wants to apply a fast-track review process normally reserved for drugs for terminal cancer and AIDS patients to drugs for diabetes and obesity.
Pfizer sues over counterfeit Lipitor Pfizer Inc. said Tuesday it was suing two companies connected to counterfeit versions of its cholesterol fighter, Lipitor, the world’s top-selling prescription medicine.
The ImClone Story: A Hyped Drug, a Tainted Icon It was, in retrospect, a festival of hype emblematic of the boom years, when technology stocks seemed to have nowhere to go but up.
Five Hurdles for Biotech The science is hot and the stocks are up. Here’s what’s needed to deliver on the promise.
San DNAgo Thanks to a fruitful partnership of academia and private enterprise, a vibrant biotech industry keeps on replicating itself.
Puncturing The ImClone Hype Could ImClone Systems’ Erbitux be a powerful cancer fighter after all? Maybe. A new study presented June 1 at a meeting of oncologists seems to boost that contention. But there are still reasons to doubt that Erbitux will be approved soon or that it will eventually be a blockbuster.